Table 4 :Response to maximal intraarterial doses of vasodilators after DHEA and placebo in diabetics versus controls
|
Vasodilator |
P-value |
||
|
Percent increase in blood flow from baseline ± SD |
|||
|
Diabetics |
Controls |
||
|
DHEA |
|||
|
NTP 10 μg/min |
317.6 ± 88.0 |
277.8 ± 117.3 |
0.40 |
|
ACH 100 μg/min |
413.7 ± 156.8 |
342.8 ± 148.6 |
0.40 |
|
VER 300 μg/min |
448.9 ± 169.7 |
323.1 ± 69.7 |
0.20 |
|
Placebo |
|||
|
NTP 10 μg/min |
364.8 ± 98.3 |
275.5 ± 66.7 |
0.10 |
|
ACH 100 μg/min |
479.5 ± 118.2 |
334.0 ± 108.6 |
0.06 |
|
VER 300 μg/min |
462.2 ± 77.5 |
356.6 ± 54.2 |
0.05 |